Cargando…
Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option?
Modulation of the immune response plays an important role in the natural history of renal cell carcinoma. Spontaneous regression of metastases has been well documented in a small percentage of patients after they undergo de-bulking nephrectomy without any additional systemic intervention. The only l...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Codon Publications
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345537/ https://www.ncbi.nlm.nih.gov/pubmed/28326252 http://dx.doi.org/10.15586/jkcvhl.2014.18 |
_version_ | 1782513742468087808 |
---|---|
author | Amin, Asim White, Richard L |
author_facet | Amin, Asim White, Richard L |
author_sort | Amin, Asim |
collection | PubMed |
description | Modulation of the immune response plays an important role in the natural history of renal cell carcinoma. Spontaneous regression of metastases has been well documented in a small percentage of patients after they undergo de-bulking nephrectomy without any additional systemic intervention. The only logical explanation for these observations is “resetting” of the balance between tumor and the host immune system that, having been overwhelmed by the tumor burden, is able to function better after tumor de-bulking. Attempts to modulate the activity of the immune system “on demand” have included the use of vaccines, cytokines/lymphokines, adoptive cell transfer, monoclonal antibodies and most recently manipulation of immune checkpoint inhibitors. Here we review the data for infusional interleukin-2 in the management of advanced renal cell carcinoma and its role in current clinical practice. |
format | Online Article Text |
id | pubmed-5345537 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Codon Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-53455372017-03-21 Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option? Amin, Asim White, Richard L J Kidney Cancer VHL Review Article Modulation of the immune response plays an important role in the natural history of renal cell carcinoma. Spontaneous regression of metastases has been well documented in a small percentage of patients after they undergo de-bulking nephrectomy without any additional systemic intervention. The only logical explanation for these observations is “resetting” of the balance between tumor and the host immune system that, having been overwhelmed by the tumor burden, is able to function better after tumor de-bulking. Attempts to modulate the activity of the immune system “on demand” have included the use of vaccines, cytokines/lymphokines, adoptive cell transfer, monoclonal antibodies and most recently manipulation of immune checkpoint inhibitors. Here we review the data for infusional interleukin-2 in the management of advanced renal cell carcinoma and its role in current clinical practice. Codon Publications 2014-11-23 /pmc/articles/PMC5345537/ /pubmed/28326252 http://dx.doi.org/10.15586/jkcvhl.2014.18 Text en Copyright © 2016 Codon Publications License: This open access article is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). http://creativecommons.org/licenses/by/4.0 |
spellingShingle | Review Article Amin, Asim White, Richard L Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option? |
title | Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option? |
title_full | Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option? |
title_fullStr | Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option? |
title_full_unstemmed | Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option? |
title_short | Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option? |
title_sort | interleukin-2 in renal cell carcinoma: a has-been or a still-viable option? |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345537/ https://www.ncbi.nlm.nih.gov/pubmed/28326252 http://dx.doi.org/10.15586/jkcvhl.2014.18 |
work_keys_str_mv | AT aminasim interleukin2inrenalcellcarcinomaahasbeenorastillviableoption AT whiterichardl interleukin2inrenalcellcarcinomaahasbeenorastillviableoption |